Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. OBJECTIVES: To examine the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD. METHODS: Mild AD patients (n = 800) were randomly assigned to 100 mg twice a day or 4 mg twice a day. Prior to unblinding, the Statistical Analysis Plan was revised to compare the 100 mg twice a day as monotherapy subgroup (n = 79) versus 4 mg twice a day as randomized (n = 396), and 4 mg twice a day as monotherapy (n = 76) versus 4 mg twice a day as add-on therapy (n = 297), with strong control of family-wise type I error. RESULTS: The revised analyses were statistically significant at the required threshold of p < 0.025 in both comparisons for change in ADAS-cog, ADCS-ADL, MRI atrophy, and glucose uptake. The brain atrophy rate was initially typical of mild AD in both add-on and monotherapy groups, but after 9 months of treatment, the rate in monotherapy patients declined significantly to that reported for normal elderly controls. Differences in severity or diagnosis at baseline between monotherapy and add-on patients did not account for significant differences in favor of monotherapy. CONCLUSIONS: The results are consistent with earlier studies in supporting the hypothesis that LMTM might be effective as monotherapy and that 4 mg twice a day may serve as well as higher doses. A further suitably randomized trial is required to test this hypothesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig.4 Annualized rate of whole brain atrophy (expressed as %) over months 0–6 and months 12–18 in monotherapy patients. The rates are compared with those reported by Leung et al. for mild AD and normal elderly controls [20].](https://figures.cochat.ai/paper-figures/aeac5f76d82b4c29866d5b5dc4b39bb2/potential-of-low-dose-leuco-methylthioninium-bis-hydromethanesulphonate-lmtm-figure-4.jpg)
![Fig.5 Voxel-based morphometric comparison showing regions of greater atrophy in patients receiving LMTM as monotherapy [N = 157] (A) or as add-on to approved treatments for AD [N = 610], (B) in TRx-237-005 compared with elderly controls [N = 244] from the ongoing Aberdeen birth cohort studies [23, 26], controlled for age, sex and total intracranial volume of each individual. (C) Voxel-based morphometric comparison of monotherapy and add-on patients in TRx-237-005. Data are displayed at a significance threshold corrected for family-wise error at the whole brain level at p < 0.05.](https://figures.cochat.ai/paper-figures/6e1dee94609a44d685c3236eb32611c9/potential-of-low-dose-leuco-methylthioninium-bis-hydromethanesulphonate-lmtm-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two earlier studies (NCT01689233 and NCT01689246) conducted on participants with mild AD and mild to moderate AD, respectively, indicated that the drug demonstrated good safety and potential benefits as a monotherapy.466,467”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [466]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Tau protein has the capacity to form toxic proteolytically resistant oligomers which seed further tau aggregation in an autocatalytic manner [10] and propagate the pathology into previously healthy brain regions [11], most likely accounting for the stereotyped pattern of spread of pathology [6, 7, 12].”
BackgroundPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“Patients were also assessed at all visits for suicidal ideation and intent using the Columbia-Suicide Severity Rating Scale [17], and were systematically monitored for potential serotonin syndrome using a rating scale derived from four published diagnostic criteria [18], because of a theoretical potential for serotoni…”
MethodA comparison of observational studies and randomized, controlled trials.
Benson, K., & Hartz, A. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422506 · Cited by 2,347
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113 · cited 1×
“In Alzheimer’s disease (AD), clinical deterioration [1], imaging markers of loss of neuronal function [2–4], and progression of brain atrophy as measured by MRI volumetry [5] progress in parallel with the accumulation of aggregated tau.”
BackgroundSelf-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 3×
“as monotherapy or as add-on therapy was also compared with that reported for mild AD in the placebo arms of recent Phase III studies [21, 22] and currently available ADNI data (https://ida.”
ResultDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · cited 1×
“Since measurable cohort differences in diagnosis or severity do not appear to explain the treatment differences we report, we believe that the within- and between-study consistency of the results cannot be dismissed lightly, particularly given the urgent need for new treatments in AD [56].”
Self-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 3×
“as monotherapy or as add-on therapy was also compared with that reported for mild AD in the placebo arms of recent Phase III studies [21, 22] and currently available ADNI data (https://ida.”
ResultAcetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404 · cited 1×
“Ascending cholinergic projections originating predominantly from nucleus basalis provide both direct activation [33] and indirect inhibitory modulation of cortical pyramidal cells [34].”
BackgroundAssociations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750 · cited 5×
“Using the same methodology as in the ADNI program [24], baseline 18F-FDG-PET SUVR in inferior temporal gyrus normalized with respect to pons was less than that reported for mild AD [24] in both monotherapy (p = 0.”
BackgroundMethodResultInfluentialProteopathic tau seeding predicts tauopathy in vivo
Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., Belaygorod, L., Cairns, N. J., Holtzman, D. M., & Diamond, M. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411649111 · Cited by 696
Lewis, D., Campbell, M., Terry, R., & Morrison, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-06-01799.1987 · Cited by 578 · cited 1×
“sites of neurofibrillary degeneration in AD [36].”
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547 · cited 1×
“Tau protein has the capacity to form toxic proteolytically resistant oligomers which seed further tau aggregation in an autocatalytic manner [10] and propagate the pathology into previously healthy brain regions [11], most likely accounting for the stereotyped pattern of spread of pathology [6, 7, 12].”
BackgroundSelf-citationMosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1039-z · Cited by 487
A comparison of observational studies and randomized, controlled trials
Benson, K., & Hartz, A. J. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00754-6 · Cited by 457
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427 · cited 4×
“The as-randomised analysis of an earlier Phase III trial (TRx237-015) has been reported [16].”
MethodResultSelf-citationBasal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
Schmitz, T. W., Nathan Spreng, R., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., Toga, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13249 · Cited by 335 · cited 1×
“Both of these basal forebrain nuclei are known to be affected by tau aggregation pathology [28, 29], and may precede cortical pathology [30].”
BackgroundMurray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324
Khatoon, S., Grundke‐Iqbal, I., & Iqbal, K. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09432.x · Cited by 304
Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297 · cited 2×
“05 M also appears to be adequate for a range of other potentially beneficial effects of the MT moiety such as enhancement of autophagy [41] and enhancement of mitochondrial function [42–49].”
BackgroundRamsay, R. R., Dunford, C., & Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707430 · Cited by 276 · cited 1×
“Patients were also assessed at all visits for suicidal ideation and intent using the Columbia-Suicide Severity Rating Scale [17], and were systematically monitored for potential serotonin syndrome using a rating scale derived from four published diagnostic criteria [18], because of a theoretical potential for serotoni…”
MethodWischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · cited 13×
“The differences between LMTM as monotherapy and add-on therapy are likewise comparable with the effect sizes found in the earlier placebo controlled monotherapy study of MTC at a comparable brain concentration of MT [13].”
BackgroundMethodResultSelf-citationSubregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study
Kilimann, I., Grothe, M., Heinsen, H., Alho, E. J. L., Grinberg, L., Amaro Jr., E., dos Santos, G. A. B., da Silva, R. E., Mitchell, A. J., Frisoni, G. B., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132345 · Cited by 232 · cited 1×
“Coordinates permitting determination of nucleus basalis volume were kindly provided by Ingo Kilimann [25].”
MethodSelf-citationCerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease
Bradley, K. M. (2002) · Brain · doi:10.1093/brain/awf185 · Cited by 203
Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert
Sassin, I., Schultz, C., Thal, D. R., Rüb, U., Arai, K., Braak, E., & Braak, H. (2000) · Acta Neuropathologica · doi:10.1007/s004019900178 · Cited by 195 · cited 1×
“Both of these basal forebrain nuclei are known to be affected by tau aggregation pathology [28, 29], and may precede cortical pathology [30].”
BackgroundMukaetova-Ladinska, E. B., Garcia-Siera, F., Hurt, J., Gertz, H. J., Xuereb, J. H., Hills, R., Brayne, C., Huppert, F. A., Paykel, E. S., McGee, M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64573-7 · Cited by 187 · cited 1×
“Tau protein has the capacity to form toxic proteolytically resistant oligomers which seed further tau aggregation in an autocatalytic manner [10] and propagate the pathology into previously healthy brain regions [11], most likely accounting for the stereotyped pattern of spread of pathology [6, 7, 12].”
BackgroundSelf-citationNeurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue
Rojas, J. C., Bruchey, A. K., & Gonzalez-Lima, F. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.007 · Cited by 172
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration
Leung, K. K., Bartlett, J. W., Barnes, J., Manning, E. N., Ourselin, S., Fox, N. C., & Initiative, F. T. A. D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e318281ccd3 · Cited by 165
Jobst, K. A., Smith, A. D., Barker, C. S., Wear, A., King, E. M., Smith, A., Anslow, P. A., Molyneux, A. J., Shepstone, B. J., & Soper, N. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.190 · Cited by 163
Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity
Stack, C., Jainuddin, S., Elipenahli, C., Gerges, M., Starkova, N., Starkov, A. A., Jové, M., Portero-Otin, M., Launay, N., Pujol, A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu080 · Cited by 159 · cited 2×
“teins in tau transgenic mice [51], and are less effective”
BackgroundBraak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 156 · cited 1×
“Proteolytically stable aggregates of tau protein can be measured in the neocortex in the prodromal phase of the disease from Braak stage 2 onwards [6–8], which occurs at least 20 years before neurofibrillary pathology is seen in neocortex or dementia symptoms appear [9], and the levels increase exponentially as the di…”
BackgroundSchneider, L. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.343 · Cited by 151
Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 143 · cited 11×
“The differences between LMTM as monotherapy and add-on therapy are likewise comparable with the effect sizes found in the earlier placebo controlled monotherapy study of MTC at a comparable brain concentration of MT [13].”
BackgroundSelf-citationThe Cerebellum in Alzheimer's Disease
Larner, A. J. (1997) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106632 · Cited by 124 · cited 1×
“We show that the difference in glucose uptake between LMTM monotherapy and add-on therapy is 2–3-fold greater in neocortical regions affected by neurofibrillary degeneration [6–8] than in cerebellum which is not affected [54].”
BackgroundMethylene blue prevents neurodegeneration caused by rotenone in the retina
Zhang, X., Rojas, J. C., & Gonzalez-Lima, F. (2006) · Neurotoxicity Research · doi:10.1007/bf03033307 · Cited by 118
Murray, A. D., Staff, R. T., McNeil, C. J., Salarirad, S., Ahearn, T. S., Mustafa, N., & Whalley, L. J. (2011) · Brain · doi:10.1093/brain/awr259 · Cited by 118
Self-citationMethylene blue alleviates nuclear and mitochondrial abnormalities in progeria
Xiong, Z., Choi, J. Y., Wang, K., Zhang, H., Tariq, Z., Wu, D., Ko, E., LaDana, C., Sesaki, H., & Cao, K. (2016) · Aging Cell · doi:10.1111/acel.12434 · Cited by 118
Cavedo, E., Grothe, M. J., Colliot, O., Lista, S., Chupin, M., Dormont, D., Houot, M., Lehéricy, S., Teipel, S., Dubois, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09780-3 · Cited by 109 · cited 1×
“The inverse relationship we report is the opposite of that reported for the response to donepezil [31], which varies in proportion with basal forebrain atrophy, and donepezil has also been shown recently to reduce the rate of progression of basal forebrain atrophy in prodromal AD [32].”
ResultHarrington, C. R., Storey, J. M. D., Clunas, S., Harrington, K. A., Horsley, D., Ishaq, A., Kemp, S. J., Larch, C. P., Marshall, C., Nicoll, S. L., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616029 · Cited by 106 · cited 13×
“The differences between LMTM as monotherapy and add-on therapy are likewise comparable with the effect sizes found in the earlier placebo controlled monotherapy study of MTC at a comparable brain concentration of MT [13].”
BackgroundSelf-citationEffects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
Melis, V., Magbagbeolu, M., Rickard, J. E., Horsley, D., Davidson, K., Harrington, K. A., Goatman, K., Goatman, E. A., Deiana, S., Close, S. P., et al. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000133 · Cited by 90 · cited 1×
“There is no doseresponse for oligomer disaggregation in vitro, and higher doses of LMTM do not result in greater reduction in tau pathology in transgenic mouse models [50].”
BackgroundSelf-citationBehavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue
Bruchey, A. K., & Gonzalez-Lima, F. (2008) · American Journal of Pharmacology and Toxicology · doi:10.3844/ajptsp.2008.72.79 · Cited by 80
Shearman, E., Rossi, S., Szász, B. K., Jurányi, Z., Fallon, S. M., Pomara, N., Sershen, H. W., & Lajtha, Á. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.12.001 · Cited by 77 · cited 1×
“Memantine also increases release of acetylcholine in nucleus accumbens [35]”
BackgroundGertz, H., Xuereb, J. H., Huppert, F. A., Brayne, C., McGee, M. A., Paykel, E. S., Harrington, C. R., Mukaetova-Ladinska, E., Arendt, T., & Wischik, C. M. (1998) · Acta Neuropathologica · doi:10.1007/s004010050780 · Cited by 70 · cited 1×
“Tau protein has the capacity to form toxic proteolytically resistant oligomers which seed further tau aggregation in an autocatalytic manner [10] and propagate the pathology into previously healthy brain regions [11], most likely accounting for the stereotyped pattern of spread of pathology [6, 7, 12].”
BackgroundSelf-citationTanaka, Y., Hanyu, H., Sakurai, H., Takasaki, M., & Abe, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000070998 · Cited by 64 · cited 1×
“The inverse relationship we report is the opposite of that reported for the response to donepezil [31], which varies in proportion with basal forebrain atrophy, and donepezil has also been shown recently to reduce the rate of progression of basal forebrain atrophy in prodromal AD [32].”
ResultLee, K. K., & Boelsterli, U. A. (2014) · Redox Biology · doi:10.1016/j.redox.2014.03.003 · Cited by 57
Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
Wischik, C. M., Schelter, B. O., Wischik, D., Storey, J. M. D., & Harrington, C. R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170727 · Cited by 54 · cited 1×
“Proteolytically stable aggregates of tau protein can be measured in the neocortex in the prodromal phase of the disease from Braak stage 2 onwards [6–8], which occurs at least 20 years before neurofibrillary pathology is seen in neocortex or dementia symptoms appear [9], and the levels increase exponentially as the di…”
BackgroundSelf-citationZakaria, A., Hamdi, N., & Abdel-Kader, R. M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9088-8 · Cited by 53
Huang, M., Felix, A. R., Flood, D., Bhuvaneswaran, C., Hilt, D., Koenig, G., & Meltzer, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3596-0 · Cited by 47 · cited 1×
“Ascending cholinergic projections originating predominantly from nucleus basalis provide both direct activation [33] and indirect inhibitory modulation of cortical pyramidal cells [34].”
BackgroundWhalley, L. J., Murray, A. D., Staff, R. T., Starr, J. M., Deary, I. J., Fox, H. C., Lemmon, H. A., Duthie, S. J., Collins, A. R., & Crawford, J. R. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.05.010 · Cited by 44 · cited 3×
“The pattern of atrophy at baseline in patients receiving LMTM as monotherapy was typical of mild AD and significantly different from a cohort of well characterized normal elderly controls [26].”
BackgroundMethodSelf-citationTau accumulation in the nucleus accumbens in tangle-predominant dementia
Kawakami, I., Hasegawa, M., Arai, T., Ikeda, K., Oshima, K., Niizato, K., Aoki, N., Omi, K., Higashi, S., Hosokawa, M., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-40 · Cited by 42 · cited 1×
“Both of these basal forebrain nuclei are known to be affected by tau aggregation pathology [28, 29], and may precede cortical pathology [30].”
BackgroundAtamna, H., Atamna, W., Al-Eyd, G., Shanower, G., & Dhahbi, J. M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.09.004 · Cited by 40
Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain
Rodriguez, P., Zhou, W., Barrett, D. W., Altmeyer, W. B., Gutierrez, J. E., Li, J., Lancaster, J. L., Gonzalez-Lima, F., & Duong, T. Q. (2016) · Radiology · doi:10.1148/radiol.2016152893 · Cited by 37 · cited 1×
“Enhancement of mitochondrial metabolism [42–49] has been proposed as a mechanism underlying acute neurocognitive benefits in wild-type rodents [46] and in healthy young human volunteers [46, 52, 53].”
BackgroundExamination of phosphorylated tau protein as a PHF-precursor at early stage alzheimer's disease
Lai, R. Y. K., Gertz, H. N.-J., Wischik, D., Xuereb, J. H., Mukaetova-Ladinska, E. B., Harrington, C. R., Edwards, P. C., Mena, R., Paykel, E. S., Brayne, C., et al. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00041-c · Cited by 36
Self-citationELISA-Quantitation of Phosphorylated Tau Protein in the Alzheimer’s Disease Brain
Herrmann, M., Golombowski, S., Kräuchi, K., Frey, P., Mourton-Gilles, C., Hulette, C., Rosenberg, C., Müller-Spahn, F., & Hock, C. (1999) · European Neurology · doi:10.1159/000008108 · Cited by 34
Alusik, S., Kalatova, D., & Palúch, Z. (2014) · PubMed · Cited by 19
Tau accumulation in the nucleus accumbens in tangle-predominant dementia
河上緒 (2014) · Cited by 16
Methylene blue modulates functional connectivity in the human brain
Rodriguez, P., Singh, A. P., Malloy, K. E., Zhou, W., Barrett, D. W., Franklin, C. G., Altmeyer, W. B., Gutierrez, J. E., Li, J., Heyl, B. L., et al. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9541-6 · Cited by 13 · cited 1×
“Enhancement of mitochondrial metabolism [42–49] has been proposed as a mechanism underlying acute neurocognitive benefits in wild-type rodents [46] and in healthy young human volunteers [46, 52, 53].”
BackgroundMurray, A. D., Staff, R. T., Ahearn, T. S., Bentham, P., Seng, K. M., & Wischik, C. M. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2454 · Cited by 7
Self-citation
Research works printed but not linked: 2
- Wischik, 2017, J Alzheimers Dis
- Gharid A , Atamna H (2011) Methylene blue induces mitochondrial complex IV and improves cognitive function and grip strength in old mice. In Neurodegeneration: Theory, Disorders and Treatments, McNeill AS , ed. AS Nova Science Publishers, Hauppauge, NY, pp. 63–85.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
“The results of TRx 237–005 phase III clinical trials showed that the agent may be effective as a monotherapy since the brain atrophy rate of AD patients declined after 9 months of treatment.(137) ACI-35 (AC Immune/Janssen) and AADvac1 (Axon Neuroscience SE) are vaccines that target the hyperphosphorylated tau protein,…”
BackgroundSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Metadata
- Authors
- Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., & Wischik, C. M.
- Affiliations
- University of Oxford (GB)
- Douglas Mental Health University Institute (CA)
- University of Geneva (CH)
- Beijing Institute for Brain Disorders (CN)
- TauRx (United Kingdom) (GB)
- Moebius-Consult, Baar, Switzerland
- Birmingham and Solihull Mental Health NHS Foundation Trust (GB)
- Salamandra LLC, Bethesda, MD, USA
- University of Aberdeen (GB)
- University of Cambridge (GB)
- CSD Biostatistics, Tucson, AZ, USA
- Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
- BioClinica, Lyon, France
- RadMD, New York, NY, USA
- MNI Imaging, New Haven, CT, USA
- Corresponding author
- Wischik, Claude M.
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-11-28
- Volume
- 61
- Issue
- 1
- Pages
- 435-457
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5734125
- OpenAlex
- W2768871557
- Cited by
- 219
- References
- 57
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 30 · 2023: 31 · 2022: 28 · 2021: 27 · 2020: 27 · 2019: 17 · 2018: 16 · 2017: 1
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- TauRx Pharmaceuticals
- European Commission
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- MeSH terms
- Mental Status and Dementia Tests, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, International Cooperation, Male, Methylene Blue, Middle Aged, Antipsychotic Agents, Cohort Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.